JPRN-UMIN000008140
Completed
Phase 2
A phase II study of Paclitaxel combined with Bevacizumab in HER2 negative metastatic Breast Cancer - KBCOG 12
Kobe Breast Cancer Oncology Group0 sites24 target enrollmentJune 12, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Kobe Breast Cancer Oncology Group
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Previously treated with bevacizumab 2\) Primary chemotherapy refractory with Paclitaxel 3\) The operation has been scheduled for the examination period 4\) Uncontrollable hypertension 5\) Symptomatic brain metastasis 6\) Anaphylaxis against drugs used in protocol treatment 7\) Uncontrollable ascites, pleural effusion 8\) Active infection, Severe complications (abnormal electrocardiogram, heart failure, arrhythmia, thromboembolism, etc) 9\) Severe infection or serious complications, such as hypoalimentation 10\) Other active malignancies 11\) Pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 12\) Doctors decision for exclusion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
Recruiting
Phase 4
Observational study of paclitaxel with Bevacizumab for advanced or recurrent breast cancer(SBCCSG-28)advanced or recurrent breast cancerJPRN-UMIN000009090Saitama Breast Cancer Clinical Study Group (SBCCSG)70
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
Recruiting
Not Applicable
Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer.cervical cancerJPRN-UMIN000012400Department of Obstetrics and Gynecology, Osaka Medical College30
Completed
Phase 2
A phase II study of Bevacizumab plus Paclitaxel followed by Eribulin maintenance therapy in patients with HER2-negative metastatic breast cancer.HER2-negative metastatic breast cancerJPRN-UMIN000015971Sairtama Breast Cancer Clinical Study Group (SBCCSG)51